PeptidePedia The community reference

Contributions of TirzTaxonomist

User contributions·45 logged edits·page 1 of 1

Contributions by TirzTaxonomist, newest first. This list covers edits recorded in the site's change log; the editor's lifetime total of 14,211 edits includes activity predating the current log.

  1. 18:00, 26 Jul 2026 (diff | hist) Asymchem Laboratories 17,160 ±0 m add the registered legal name exactly as it appears in the registry record
  2. 12:20, 15 Jul 2026 (diff | hist) Oral semaglutide 4,582 ±0 m reorder the analogues chronologically rather than alphabetically
  3. 17:00, 20 Jun 2026 (diff | hist) Retatrutide 7,421 ±0 add category for the drug class
  4. 11:20, 12 Jun 2026 (diff | hist) Talk:Dose escalation schedule 674 +109 /* Tirzepatide table row */ new section
  5. 14:05, 25 May 2026 (diff | hist) Talk:Receptor bias 748 +60 /* Two senses of bias */ reply
  6. 18:46, 21 May 2026 (diff | hist) Melanotan II 4,649 ±0 state which receptor subtype the binding data refers to
  7. 02:58, 13 May 2026 (diff | hist) Oral semaglutide 4,582 ±0 fix the amino-acid substitution — position 8, not position 2
  8. 14:10, 6 May 2026 (diff | hist) Talk:SURMOUNT trial programme 748 +149 /* Tolerability at larger effect */ reply
  9. 22:10, 2 May 2026 (diff | hist) GL Biochem (Shanghai) 16,491 ±0 add the lead time for catalogue lines, as reported
  10. 09:06, 17 Apr 2026 (diff | hist) Loss on drying 4,874 ±0 expand §Why the distinction from water matters
  11. 04:41, 31 Mar 2026 (diff | hist) Subcutaneous injection 5,293 ±0 add category for preparation and handling
  12. 02:34, 24 Mar 2026 (diff | hist) PolyPeptide Group (Hangzhou) 18,363 +495 expand §Independent testing record
  13. 09:08, 20 Feb 2026 (diff | hist) Talk:Tirzepatide 822 +92 /* SURPASS-2 comparator dose */ reply
  14. 10:15, 19 Feb 2026 (diff | hist) Talk:Tirzepatide 400 +234 /* SURPASS-2 comparator dose */ new section
  15. 02:17, 5 Jan 2026 (diff | hist) Oral semaglutide 4,582 ±0 expand §Clinical position
  16. 08:14, 24 Dec 2025 (diff | hist) GLP-1 receptor 7,570 ±0 add category for receptor pharmacology
  17. 16:05, 17 Sep 2025 (diff | hist) Amylin 5,795 +696 m move the trade-name history out of the lead and into §Regulatory history
  18. 22:53, 18 Aug 2025 (diff | hist) Counterfeit peptide 4,926 +673 m expand §Dilution with bulking agent
  19. 07:43, 18 Aug 2025 (diff | hist) International nonproprietary name 4,356 +356 m add see also to the amylin analogue
  20. 12:30, 7 Aug 2025 (diff | hist) Orforglipron 5,373 ±0 state the substitution in one-letter code as well, per PP:MOS
  21. 20:02, 15 Jul 2025 (diff | hist) Cagrilintide 4,052 ±0 m convert a hard-coded date to the house format
  22. 10:11, 22 Jun 2025 (diff | hist) Amylin 4,449 +172 add the peptide length to the infobox
  23. 08:27, 13 Jun 2025 (diff | hist) Qingdao Saber Technology Pharmaceutical 2,118 +360 m sentence case in headings per PP:MOS
  24. 09:52, 4 Jun 2025 (diff | hist) Dulaglutide 5,130 +969 give the strength per pen as well as per millilitre
  25. 00:40, 24 May 2025 (diff | hist) Survodutide 4,510 ±0 rm the equipotency claim — the cited paper does not make it
  26. 10:43, 13 May 2025 (diff | hist) Retatrutide 5,894 ±0 add the molecular formula to the infobox
  27. 04:42, 13 May 2025 (diff | hist) Incretin effect 5,933 +165 add the enteroendocrine cell type responsible for secretion
  28. 02:16, 5 Apr 2025 (diff | hist) Cost per milligram 3,001 +854 correct the deductible description
  29. 12:55, 1 Apr 2025 (diff | hist) GLP-1 receptor 6,418 +313 m expand §Distribution and its clinical consequences
  30. 12:56, 17 Mar 2025 (diff | hist) International nonproprietary name 3,145 ±0 give the strength per pen as well as per millilitre
  31. 12:28, 13 Mar 2025 (diff | hist) MOTS-c 2,696 +33 add the parent protein and the residue range the fragment spans
  32. 04:23, 26 Feb 2025 (diff | hist) Glucagon 5,754 +841 the half-life in the lead was the terminal figure; label it as such
  33. 21:04, 16 Dec 2024 (diff | hist) Trial data comparison 1,514 +177 add the worked example that matches the default inputs
  34. 20:40, 8 Dec 2024 (diff | hist) Liquid chromatography-mass spectrometry 2,642 ±0 rm the claim that the method is stability-indicating without a forced-degradation study
  35. 18:54, 2 Dec 2024 (diff | hist) Vial filling and stoppering 2,748 +268 state that overlay gas is used and name it
  36. 08:19, 29 Nov 2024 (diff | hist) Amino acid analysis 2,367 +324 split §Principle from §Practical limitations
  37. 21:32, 3 Nov 2024 (diff | hist) CagriSema 2,261 +38 m space between number and unit per PP:MOS
  38. 12:06, 1 Nov 2024 (diff | hist) Glucagon 4,197 +83 m give the isoelectric point with the method it was determined by
  39. 17:16, 18 Oct 2024 (diff | hist) FLOW trial 1,950 ±0 split the results table so the two doses are separate rows
  40. 04:41, 2 Sep 2024 (diff | hist) Reverse-phase HPLC 3,012 +268 space between number and unit per PP:MOS
  41. 20:58, 30 Aug 2024 (diff | hist) Amylin 1,269 +1,269 N start article on the compound
  42. 16:09, 21 Aug 2024 (diff | hist) Peptide synthesis 2,798 +40 give the closure integrity test by name
  43. 18:53, 8 Aug 2024 (diff | hist) Timeline of incretin therapeutics 1,845 +742 m reorder the analogues chronologically rather than alphabetically
  44. 19:57, 30 Jul 2024 (diff | hist) Dual incretin agonist 2,297 ±0 expand §Beyond GIP and GLP-1
  45. 07:58, 24 Jul 2024 (diff | hist) Karl Fischer titration 2,412 ±0 m give the limit of quantitation with the signal-to-noise ratio it assumes